HASBROUCK HEIGHTS, NJ--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that a large new 3 year follow-up study of NX-1207 for benign prostatic hyperplasia (BPH) is near completion. The study evaluated symptomatic progress of over one hundred subjects involved in the Company’s Phase 2 U.S. clinical trial initiated in 2005. Individuals in the study were assessed 3 years after NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. This is the largest cohort of patients treated with NX-1207 followed for as long as 3 years thus far. The Company anticipates the reporting of final results and statistical analysis for the study within the next 2-3 weeks.
